Lenti‐GDNF Gene Therapy Protects Against Alzheimer's Disease‐Like Neuropathology in 3xTg‐AD Mice and MC65 Cells
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Summary: Aims: Glial cell‐derived neurotrophic factor (GDNF) is emerging as a potent neurotrophic factor with therapeutic potential against a range of neurodegenerative conditions including Alzheimer's disease (AD). We assayed the effects of GDNF treatment in AD experimental models through gene‐therapy procedures. Methods: Recombinant lentiviral vectors were used to overexpress GDNF gene in hippocampal astrocytes of 3xTg‐AD mice in vivo, and also in the MC65 human neuroblastoma that conditionally overexpresses the 99‐residue carboxyl‐terminal (C99) fragment of the amyloid precursor protein. Results: After 6 months of overexpressing GDNF, 10‐month‐old 3xTg‐AD mice showed preserved learning and memory, while their counterparts transduced with a green fluorescent protein vector showed cognitive loss. GDNF therapy did not significantly reduce amyloid and tau pathology, but rather, induced a potent upregulation of brain‐derived neurotrophic factor that may act in concert with GDNF to protect neurons from atrophy and degeneration. MC65 cells overexpressing GDNF showed an abolishment of oxidative stress and cell death that was at least partially mediated by a reduced presence of intracellular C99 and derived amyloid β oligomers. Conclusions: GDNF induced neuroprotection in the AD experimental models used. Lentiviral vectors engineered to overexpress GDNF showed to be safe and effective, both as a potential gene therapy and as a tool to uncover the mechanisms of GDNF neuroprotection, including cross talk between astrocytes and neurons in the injured brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Hydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885
Mechanisms of CaMKII action in long-term potentiation
Lisman, J., Yasuda, R., & Raghavachari, S. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3192 · Cited by 1,134
Gene-expression profile of the ageing brain in mice
Lee, C.-K., Weindruch, R., & Prolla, T. A. (2000) · Nature Genetics · doi:10.1038/77046 · Cited by 1,055
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“Analysis of GDNF in human brain has demonstrated a decrease in substantia nigra in Parkinson’s disease (PD) [3], but its regulation in Alzheimer’s disease (AD) brain is poorly documented.”
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 2×
“BDNF has already been demonstrated to induce a broad neuroprotection in several models of AD, including reversion of synapse loss and restoration of learning and memory in APPTg mice and prevention of death induced by Ab in primary neuron cultures [28].”
Pro‐regenerative properties of cytokine‐activated astrocytes
Liberto, C. M., Albrecht, P. J., Herx, L. M., Yong, V. W., & Levison, S. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02420.x · Cited by 464
Zhu, X., Rottkamp, C. A., Boux, H., Takeda, A., Perry, G., & Smith, M. A. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.10.880 · Cited by 378 · cited 1×
“Regarding tau pathology, several oxidative stress-induced mechanisms have been demonstrated to exacerbate hyperphosphorylation of tau [63,64].”
Rodríguez, J. J., Jones, V. C., Tabuchi, M., Allan, S. M., Knight, E. M., LaFerla, F. M., Oddo, S., & Verkhratsky, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002935 · Cited by 377
Cited by
The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease
Josiane, Tatiani, Francielle, Michelle, & Alexandra (2015) · Aging and disease · doi:10.14336/ad.2015.0825 · Cited by 407
Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201
Metrnl: A secreted protein with new emerging functions
Zheng, S.-L., Li, Z.-Y., Song, J., Liu, J.-M., & Miao, C.-Y. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.9 · Cited by 190
Cell secretome: basic insights and therapeutic opportunities for CNS disorders
Pinho, A. G., Cibrão, J. R., Silva, N. A., Monteiro, S., & Salgado, A. J. (2020) · Pharmaceuticals · doi:10.3390/ph13020031 · Cited by 94
Neuroprotective Effects of Exercise Treatments after Injury: The Dual Role of Neurotrophic Factors
Cobianchi, S., Arbat-Plana, A., Lopez-Alvarez, V. M., & Navarro, X. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160330105132 · Cited by 94
Gene Therapy Strategies for Alzheimer's Disease: An Overview
Alves, S., Fol, R., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.017 · Cited by 45
Alzheimer’s Disease: Dawn of a New Era?
Amirrad, F., Bousoik, E., Shamloo, K., Al-Shiyab, H., Nguyen, V.-H. V., & Montazeri Aliabadi, H. (2017) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vs8p · Cited by 21
“Also, transfection with GDNFexpressing gene using a lentiviral vector has improved cognitive mechanisms in a transgenic mice model of AD (186).”
Method
Metadata
- Authors
- Revilla, S., Ursulet, S., Álvarez‐López, M. J., Castro‐Freire, M., Perpiñá, U., García‐Mesa, Y., Bortolozzi, A., Giménez‐Llort, L., Kaliman, P., Cristòfol, R., Sarkis, C., & Sanfeliu, C.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2014-08-13
- Volume
- 20
- Issue
- 11
- Pages
- 961-972
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W1981527089
- Cited by
- 109
- References
- 14
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.